StonvexLoading…
StonvexStonvexStonvexCore line items from NUS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $1.49B | $1.73B | $1.97B | $2.23B |
Operating Income | $65.76M | $-151.59M | $48.27M | $110.85M |
Net Income | $160.20M | $-146.59M | $8.60M | $104.78M |
EPS (Diluted) | $3.18 | $-2.95 | $0.17 | $2.07 |
Total Assets | $1.41B | $1.47B | $1.81B | $1.82B |
Total Liabilities | $600.07M | $817.46M | $986.66M | $923.67M |
Cash & Equivalents | $238.63M | $186.88M | $256.06M | $264.73M |
Free Cash Flow OCF − CapEx | $46.01M | $70.16M | $60.15M | $49.01M |
Shares Outstanding | 50.30M | 49.66M | 49.86M | 50.52M |